Effect of growth hormone on follicular fluid androgen levels in patients treated with gonadotropins before in vitro fertilization

1996 ◽  
Vol 134 (2) ◽  
pp. 190-196 ◽  
Author(s):  
Christina Bergh ◽  
Kjell Carlström ◽  
Ulrika Selleskog ◽  
Torbjörn Hillensjö
Keyword(s):  
Growth Hormone ◽  
In Vitro Fertilization ◽  
Follicular Fluid ◽  
Poor Responders ◽  
Vitro Fertilization ◽  
Igf I ◽  
Activity Ratios ◽  
Igf Binding ◽  
Androgen Levels

Bergh C, Carlström K, Selleskog U, Hillensjö T. Effect of growth hormone on follicular fluid androgen levels in patients treated with gonadotropins before in vitro fertilization. Eur J Endocrinol 1996;134:190–6. ISSN 0804–4643 Forty normally ovulating women aged 25–38 years from one private and two university in vitro fertilization (IVF) centres were used in this randomized, double-blind, parallel, placebo-controlled study to explore the effect of recombinant human growth hormone (GH) on follicular fluid (FF) levels of steroid hormones, particularly androgens. All the women had tubal factor infertility and were classified as poor responders with at least two previously performed and failed IVF treatments in which less than five oocytes had been retrieved following ovarian hyperstimulation. Growth hormone (GH 0.1 IU/kg body wt per day) or placebo was given as pretreatment during down-regulation with gonadotropin-releasing hormone agonist and during stimulation with human menopausal gonadotropin (hMG) according to the randomized protocol. Follicular fluid concentrations of steroids were measured and changes related to the levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 1 and 3 and to the mode of GH administration. Pretreatment with GH, i.e. administration of GH before hMG stimulation only, caused significantly elevated follicular fluid concentrations of estrone, testosterone and dehydroepiandrosterone (DHEA) and higher values for markers of aromatase activity (ratios between estrone and androstenedione and between estradiol-17β and androstenedione) than in the placebo group, as well as in the two groups receiving GH during hMG stimulation. The highest values for markers of steroid sulfatase activity (ratios between DHA and DHEA sulfate and between unconjugated and conjugated estrone) were found in the patients pretreated with GH. Positive correlations were found between follicular fluid IGF-I and IGF binding protein 3 on the one hand and androgens on the other. This study showed that the administration of adjuvant GH to women who were poor responders to gonadotropins alters the endocrine/paracrine ovarian response to gonadotropins. Torbjörn Hillensjö, Department of Obstetrics and Gynecology, Huddinge University Hospital, S-141 86 Huddinge, Sweden

scholarly journals Growth hormone treatment strategies in assisted reproduction for the poor responder patients

2019 ◽  
Vol 14 (2) ◽  
Author(s):  
Liailia Kh. Dzhemlikhanova ◽  
Ksenia V. Ob’edkova ◽  
Dariko A. Niauri ◽  
Igor Yu. Kogan ◽  
Maria A. Mazilina ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Follicular Fluid ◽  
Treatment Strategies ◽  
Hormone Treatment ◽  
Poor Responder ◽  
Poor Responders ◽  
Igf I ◽  
Igf Binding ◽  
Antagonist Protocol ◽  
Igfbp 3

The goal of the study was to estimate the efficacy of growth hormone (GH) co-treatment to the antagonist protocol in IVF/ ICSI cycles in poor responders. A prospective observational study involved 75 patients. All patients underwent standard antagonist protocol with or without GH co-treatment. GH additional was given a daily subcutaneous injection of 1.33 mg (equivalent to 4 IU) of GH from day 1 of ovarian stimulation until the day of human chorionic gonadotropin (hCG). Concentrations of GH, insulin-like growth factor I (IGF-I) and IGF binding protein-3 (IGFBP-3) in serum and follicular fluid were analyzed. The GH co-treatment significantly lowered effective dose of gonadotropins, duration of stimulation, IGFBP-3 level in serum and follicular fluid day of oocytes retrieval. The number of oocytes recovered, metaphase II stage (MII) oocytes, 2 pronucleus (2 pn) zygote, good-quality transferred embryos were significantly higher in the GH+ group. Only patients GH+ group became pregnant. Positive correlation was found between IGF-I level in follicular fluid, dynamics of IGFBP-3 level changes during stimulation protocol and number of good-quality transferred embryos in the GH+ group. GH administration in IVF/ICSI cycles for poor responders raises ovarian sensitivity to the gonadotropin exogenous influence, this way, increasing number of high-quality embryos and the probability of pregnancy.

scholarly journals In Vitro Fertilization Improves Childhood Growth and Metabolism

2007 ◽  
Vol 92 (9) ◽  
pp. 3441-3445 ◽  
Author(s):  
Harriet L. Miles ◽  
Paul L. Hofman ◽  
John Peek ◽  
Mark Harris ◽  
Dyanne Wilson ◽  
...  
Keyword(s):  
In Vitro Fertilization ◽  
High Density Lipoprotein ◽  
Lipid Profile ◽  
Density Lipoprotein ◽  
High Density ◽  
Vitro Fertilization ◽  
Igf I ◽  
Igf Binding

Abstract Background: There is limited information regarding the long-term outcome of children born after in vitro fertilization (IVF), although an increase in rare imprinted gene disorders such as Beckwith-Wiedemann syndrome has been reported. Methods: We recruited healthy, prepubertal children born at term after singleton pregnancy. The children in the study group were conceived using IVF with fresh embryo transfer, whereas controls were naturally conceived. Anthropometric measurements, bone age, dual-energy x-ray absorptiometry, fasting serum glucose, insulin, lipid profile, IGF-I and -II, and IGF-binding proteins 1, 2, and 3 were performed. Results: There were 69 IVF children aged 5.9 ± 0.2 yr and 71 control children aged 6.9 yr. IVF children were taller than controls when corrected for parents’ heights (height sd score of 1.05 ± 0.1 vs. 0.51 ± 0.11, P = 0.001) with higher levels of serum IGF-II (850 ± 24 vs. 773 ± 24 μg/liter, P = 0.03), higher IGF-I to IGF-binding protein 3 ratio (P = 0.04), and a trend toward higher IGF-I (105 ± 4 vs. 92 ± 4 μg/liter, P = 0.06). IVF children had higher high-density lipoprotein (1.67 ± 0.04 mmol/liter vs. 1.53 ± 0.04 mmol/liter, P = 0.02), lower triglycerides (0.65 ± 0.04 mmol/liter vs. 0.78 ± 0.04 mmol/liter, P = 0.02), and a lower total to high-density lipoprotein cholesterol ratio (2.58 vs. 2.86, P = 0.01). There were no differences in body composition. Conclusions: IVF children are taller with higher IGF-I and IGF-II levels and have a slightly more favorable lipid profile. We speculate that IVF results in epigenetic change through altered methylation of genes involved in growth and metabolism. IVF programs should consider long-term longitudinal follow-up of IVF offspring.

Sign in / Sign up

Export Citation Format

Share Document